EUVIMEDEUVIMED entdecken
Crossref

Effective treatment of human prostate carcinoma xenografts with Single-Dose PSMA-targeted [211At]YF2

Yutian Feng, Truc T Huynh, Yongxiang Zheng, Rebecca L Banks, Martin G Pomper, Ganesan Vaidyanathan, Michael R Zalutsky iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026-03 · 53 (4) · 2304-2313

DOI: 10.1007/s00259-025-07578-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 30.10.2025. Verfasst von Yutian Feng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Duke University Medical Center, Durham, NC, 27710, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Glutamate Carboxypeptidase II, Astatine, Antigens, Surface. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: NCI NIH HHS, Z-Alpha Therapeutics, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: [211At]YF2 exhibits high cytotoxicity in vitro and prolonged retention in prostate-specific membrane antigen (PSMA) expressing xenografts. Herein we evaluated its therapeutic efficacy in athymic mice with PSMA + PC3 xenografts. METHODS: The antitumor efficacy of single-dose [211At]YF2 prepared with HPLC purification and no iodo YF2 carrier (Experiment 1) and without HPLC purification with iodo YF2 carrier (Experiments 2 and 3) was evaluated: Experiment (1) groups of mice (n = 10) received PBS as control, 1.5 MBq, and 2.2 MBq [211At]YF2; Experiment (2) groups of mice (n = 10) received PBS, 2, 3, 5, or 8 MBq of [211At]YF2; and Experiment (3) groups of mice (n = 5) received PBS, 9 MBq or 12 MBq [211At]YF2. After treatment, mice were monitored for tumor growth and body weight, and the maximum tolerated dose (MTD) was determined. RESULTS: Co-administration of iodinated YF2 resulted in a 5-fold increase in tumor-to-kidney dose ratio for [211At]YF2. Significant tumor growth inhibition (TGI) and survival benefit were seen for mice treated with [211At]YF2, and a single dose of 2.2 MBq led to a 3.6-fold increase in median survival. In second study, a dose-dependent TGI and survival benefit was observed for the treatment groups, with 8 MBq of [211At]YF2 inducing a 4.5-fold increase in median survival. Radiation toxicity was seen in mice treated with 9 or 12 MBq [211At]YF2, indicating an MTD of 8 MBq. CONCLUSION: Single dose of [211At]YF2 showed significant antitumor efficacy and survival benefit at all doses with several long-term survivors, and a single dose of 8 MBq [211At]YF2 was well tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGlutamate Carboxypeptidase IIAstatineAntigens, SurfaceAnimalsMaleHumansMiceXenograft Model Antitumor AssaysRadiopharmaceuticalsCell Line, TumorMice, Nude

Stichwörter der Autor:innen

211AstatinePSMAProstate cancerTargeted alpha therapy

Substanzen

Glutamate Carboxypeptidase IIAstatineAstatine-211Antigens, SurfaceRadiopharmaceuticalsFOLH1 protein, human

Autor:innen und Institutionen

  • Department of Radiology, Duke University Medical Center, Durham, NC, 27710, USA.
  • Department of Radiology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
  • Department of Radiology, Duke University Medical Center, Durham, NC, 27710, USA. zalut001@mc.duke.edu.

ORCID-Profile: Michael R Zalutsky

Förderung

  • NCI NIH HHS
  • Z-Alpha Therapeutics
  • National Cancer Institute

Zitieren

APA

Feng, Y., Huynh, T. T., Zheng, Y., Banks, R. L., Pomper, M. G., Vaidyanathan, G., & Zalutsky, M. R. (2026). Effective treatment of human prostate carcinoma xenografts with Single-Dose PSMA-targeted [211At]YF2. European Journal of Nuclear Medicine and Molecular Imaging, 53(4), 2304-2313. https://doi.org/10.1007/s00259-025-07578-4

Vancouver

Feng Y, Huynh TT, Zheng Y, Banks RL, Pomper MG, Vaidyanathan G, et al. Effective treatment of human prostate carcinoma xenografts with Single-Dose PSMA-targeted [211At]YF2. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(4):2304-2313. doi:10.1007/s00259-025-07578-4

BibTeX
@article{Feng2026,
  author = {Feng, Yutian and Huynh, Truc T and Zheng, Yongxiang and Banks, Rebecca L and Pomper, Martin G and Vaidyanathan, Ganesan and Zalutsky, Michael R},
  title = {Effective treatment of human prostate carcinoma xenografts with Single-Dose PSMA-targeted [211At]YF2},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {4},
  pages = {2304--2313},
  doi = {10.1007/s00259-025-07578-4}
}
Kostenlos starten →